nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—SLCO1B3—Cabazitaxel—prostate cancer	0.11	0.156	CbGbCtD
Valsartan—SLCO1B3—Conjugated Estrogens—prostate cancer	0.0701	0.0997	CbGbCtD
Valsartan—SLCO1B1—Cabazitaxel—prostate cancer	0.0639	0.0908	CbGbCtD
Valsartan—SLCO1B1—Estrone—prostate cancer	0.0624	0.0887	CbGbCtD
Valsartan—SLCO1B3—Estradiol—prostate cancer	0.0615	0.0875	CbGbCtD
Valsartan—ALB—Abiraterone—prostate cancer	0.0473	0.0672	CbGbCtD
Valsartan—SLCO1B1—Conjugated Estrogens—prostate cancer	0.0408	0.058	CbGbCtD
Valsartan—SLCO1B3—Docetaxel—prostate cancer	0.0368	0.0523	CbGbCtD
Valsartan—SLCO1B1—Estradiol—prostate cancer	0.0358	0.051	CbGbCtD
Valsartan—ALB—Estrone—prostate cancer	0.0342	0.0486	CbGbCtD
Valsartan—CYP2C9—Nilutamide—prostate cancer	0.0307	0.0437	CbGbCtD
Valsartan—CYP2C9—Bicalutamide—prostate cancer	0.0307	0.0437	CbGbCtD
Valsartan—ALB—Estradiol—prostate cancer	0.0196	0.0279	CbGbCtD
Valsartan—CYP2C9—Estrone—prostate cancer	0.0184	0.0262	CbGbCtD
Valsartan—ALB—Prednisone—prostate cancer	0.0169	0.024	CbGbCtD
Valsartan—CYP2C9—Capecitabine—prostate cancer	0.014	0.0198	CbGbCtD
Valsartan—CYP2C9—Estradiol—prostate cancer	0.0106	0.015	CbGbCtD
Valsartan—Losartan—UGT2B17—prostate cancer	0.00305	0.679	CrCbGaD
Valsartan—Tasosartan—CYP3A4—prostate cancer	0.000311	0.0693	CrCbGaD
Valsartan—Losartan—CYP3A5—prostate cancer	0.000304	0.0678	CrCbGaD
Valsartan—Losartan—ACE—prostate cancer	0.00028	0.0625	CrCbGaD
Valsartan—Losartan—CYP2C19—prostate cancer	0.000207	0.0461	CrCbGaD
Valsartan—Irbesartan—CYP3A4—prostate cancer	0.000204	0.0455	CrCbGaD
Valsartan—Losartan—CYP3A4—prostate cancer	0.000132	0.0293	CrCbGaD
Valsartan—Sinusitis—Epirubicin—prostate cancer	8.11e-05	0.000406	CcSEcCtD
Valsartan—Diarrhoea—Mitoxantrone—prostate cancer	8.09e-05	0.000405	CcSEcCtD
Valsartan—Dry mouth—Capecitabine—prostate cancer	8.07e-05	0.000404	CcSEcCtD
Valsartan—Vomiting—Estradiol—prostate cancer	8.07e-05	0.000404	CcSEcCtD
Valsartan—Gastrointestinal pain—Etoposide—prostate cancer	8.04e-05	0.000403	CcSEcCtD
Valsartan—Shock—Docetaxel—prostate cancer	8.04e-05	0.000403	CcSEcCtD
Valsartan—Nervous system disorder—Docetaxel—prostate cancer	8.02e-05	0.000401	CcSEcCtD
Valsartan—Thrombocytopenia—Docetaxel—prostate cancer	8e-05	0.000401	CcSEcCtD
Valsartan—Rash—Estradiol—prostate cancer	8e-05	0.000401	CcSEcCtD
Valsartan—Infestation—Doxorubicin—prostate cancer	8e-05	0.0004	CcSEcCtD
Valsartan—Infestation NOS—Doxorubicin—prostate cancer	8e-05	0.0004	CcSEcCtD
Valsartan—Dermatitis—Estradiol—prostate cancer	7.99e-05	0.0004	CcSEcCtD
Valsartan—Headache—Estradiol—prostate cancer	7.95e-05	0.000398	CcSEcCtD
Valsartan—Skin disorder—Docetaxel—prostate cancer	7.94e-05	0.000397	CcSEcCtD
Valsartan—Oedema—Capecitabine—prostate cancer	7.91e-05	0.000396	CcSEcCtD
Valsartan—Angioedema—Prednisone—prostate cancer	7.89e-05	0.000395	CcSEcCtD
Valsartan—Renal failure—Doxorubicin—prostate cancer	7.86e-05	0.000394	CcSEcCtD
Valsartan—Infection—Capecitabine—prostate cancer	7.86e-05	0.000394	CcSEcCtD
Valsartan—Urticaria—Etoposide—prostate cancer	7.81e-05	0.000391	CcSEcCtD
Valsartan—Haemoglobin—Epirubicin—prostate cancer	7.8e-05	0.00039	CcSEcCtD
Valsartan—Anorexia—Docetaxel—prostate cancer	7.79e-05	0.00039	CcSEcCtD
Valsartan—Shock—Capecitabine—prostate cancer	7.79e-05	0.00039	CcSEcCtD
Valsartan—Rhinitis—Epirubicin—prostate cancer	7.78e-05	0.000389	CcSEcCtD
Valsartan—Abdominal pain—Etoposide—prostate cancer	7.78e-05	0.000389	CcSEcCtD
Valsartan—Nervous system disorder—Capecitabine—prostate cancer	7.76e-05	0.000388	CcSEcCtD
Valsartan—Vertigo—Prednisone—prostate cancer	7.76e-05	0.000388	CcSEcCtD
Valsartan—Haemorrhage—Epirubicin—prostate cancer	7.76e-05	0.000388	CcSEcCtD
Valsartan—Hepatitis—Epirubicin—prostate cancer	7.76e-05	0.000388	CcSEcCtD
Valsartan—Thrombocytopenia—Capecitabine—prostate cancer	7.75e-05	0.000388	CcSEcCtD
Valsartan—Syncope—Prednisone—prostate cancer	7.75e-05	0.000388	CcSEcCtD
Valsartan—Pharyngitis—Epirubicin—prostate cancer	7.7e-05	0.000386	CcSEcCtD
Valsartan—Skin disorder—Capecitabine—prostate cancer	7.69e-05	0.000385	CcSEcCtD
Valsartan—Urinary tract disorder—Epirubicin—prostate cancer	7.66e-05	0.000384	CcSEcCtD
Valsartan—Hypotension—Docetaxel—prostate cancer	7.64e-05	0.000382	CcSEcCtD
Valsartan—Connective tissue disorder—Epirubicin—prostate cancer	7.63e-05	0.000382	CcSEcCtD
Valsartan—Urethral disorder—Epirubicin—prostate cancer	7.61e-05	0.000381	CcSEcCtD
Valsartan—Loss of consciousness—Prednisone—prostate cancer	7.59e-05	0.00038	CcSEcCtD
Valsartan—Epistaxis—Doxorubicin—prostate cancer	7.54e-05	0.000378	CcSEcCtD
Valsartan—Anorexia—Capecitabine—prostate cancer	7.54e-05	0.000378	CcSEcCtD
Valsartan—Nausea—Estradiol—prostate cancer	7.54e-05	0.000377	CcSEcCtD
Valsartan—Vomiting—Mitoxantrone—prostate cancer	7.52e-05	0.000376	CcSEcCtD
Valsartan—Sinusitis—Doxorubicin—prostate cancer	7.5e-05	0.000376	CcSEcCtD
Valsartan—Rash—Mitoxantrone—prostate cancer	7.46e-05	0.000373	CcSEcCtD
Valsartan—Dermatitis—Mitoxantrone—prostate cancer	7.45e-05	0.000373	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.45e-05	0.000373	CcSEcCtD
Valsartan—Headache—Mitoxantrone—prostate cancer	7.41e-05	0.000371	CcSEcCtD
Valsartan—Hypotension—Capecitabine—prostate cancer	7.4e-05	0.00037	CcSEcCtD
Valsartan—Insomnia—Docetaxel—prostate cancer	7.39e-05	0.00037	CcSEcCtD
Valsartan—Arthralgia—Prednisone—prostate cancer	7.35e-05	0.000368	CcSEcCtD
Valsartan—Myalgia—Prednisone—prostate cancer	7.35e-05	0.000368	CcSEcCtD
Valsartan—Paraesthesia—Docetaxel—prostate cancer	7.34e-05	0.000367	CcSEcCtD
Valsartan—Anxiety—Prednisone—prostate cancer	7.33e-05	0.000367	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	7.3e-05	0.000366	CcSEcCtD
Valsartan—Dyspnoea—Docetaxel—prostate cancer	7.29e-05	0.000365	CcSEcCtD
Valsartan—Somnolence—Docetaxel—prostate cancer	7.27e-05	0.000364	CcSEcCtD
Valsartan—Hypersensitivity—Etoposide—prostate cancer	7.25e-05	0.000363	CcSEcCtD
Valsartan—Haemoglobin—Doxorubicin—prostate cancer	7.22e-05	0.000361	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Capecitabine—prostate cancer	7.21e-05	0.000361	CcSEcCtD
Valsartan—Cardiac disorder—Epirubicin—prostate cancer	7.2e-05	0.00036	CcSEcCtD
Valsartan—Rhinitis—Doxorubicin—prostate cancer	7.2e-05	0.00036	CcSEcCtD
Valsartan—Dyspepsia—Docetaxel—prostate cancer	7.2e-05	0.00036	CcSEcCtD
Valsartan—Haemorrhage—Doxorubicin—prostate cancer	7.18e-05	0.000359	CcSEcCtD
Valsartan—Hepatitis—Doxorubicin—prostate cancer	7.18e-05	0.000359	CcSEcCtD
Valsartan—Insomnia—Capecitabine—prostate cancer	7.16e-05	0.000358	CcSEcCtD
Valsartan—Pharyngitis—Doxorubicin—prostate cancer	7.13e-05	0.000357	CcSEcCtD
Valsartan—Paraesthesia—Capecitabine—prostate cancer	7.11e-05	0.000356	CcSEcCtD
Valsartan—Decreased appetite—Docetaxel—prostate cancer	7.11e-05	0.000356	CcSEcCtD
Valsartan—Urinary tract disorder—Doxorubicin—prostate cancer	7.09e-05	0.000355	CcSEcCtD
Valsartan—Gastrointestinal disorder—Docetaxel—prostate cancer	7.06e-05	0.000353	CcSEcCtD
Valsartan—Asthenia—Etoposide—prostate cancer	7.06e-05	0.000353	CcSEcCtD
Valsartan—Connective tissue disorder—Doxorubicin—prostate cancer	7.06e-05	0.000353	CcSEcCtD
Valsartan—Dyspnoea—Capecitabine—prostate cancer	7.06e-05	0.000353	CcSEcCtD
Valsartan—Oedema—Prednisone—prostate cancer	7.05e-05	0.000353	CcSEcCtD
Valsartan—Anaphylactic shock—Prednisone—prostate cancer	7.05e-05	0.000353	CcSEcCtD
Valsartan—Fatigue—Docetaxel—prostate cancer	7.05e-05	0.000353	CcSEcCtD
Valsartan—Angiopathy—Epirubicin—prostate cancer	7.04e-05	0.000352	CcSEcCtD
Valsartan—Urethral disorder—Doxorubicin—prostate cancer	7.04e-05	0.000352	CcSEcCtD
Valsartan—Nausea—Mitoxantrone—prostate cancer	7.02e-05	0.000352	CcSEcCtD
Valsartan—Immune system disorder—Epirubicin—prostate cancer	7.01e-05	0.000351	CcSEcCtD
Valsartan—Infection—Prednisone—prostate cancer	7e-05	0.000351	CcSEcCtD
Valsartan—Mediastinal disorder—Epirubicin—prostate cancer	6.99e-05	0.00035	CcSEcCtD
Valsartan—Constipation—Docetaxel—prostate cancer	6.99e-05	0.00035	CcSEcCtD
Valsartan—Dyspepsia—Capecitabine—prostate cancer	6.97e-05	0.000349	CcSEcCtD
Valsartan—Pruritus—Etoposide—prostate cancer	6.96e-05	0.000348	CcSEcCtD
Valsartan—Shock—Prednisone—prostate cancer	6.94e-05	0.000347	CcSEcCtD
Valsartan—Nervous system disorder—Prednisone—prostate cancer	6.91e-05	0.000346	CcSEcCtD
Valsartan—Decreased appetite—Capecitabine—prostate cancer	6.88e-05	0.000344	CcSEcCtD
Valsartan—Alopecia—Epirubicin—prostate cancer	6.86e-05	0.000343	CcSEcCtD
Valsartan—Skin disorder—Prednisone—prostate cancer	6.85e-05	0.000343	CcSEcCtD
Valsartan—Gastrointestinal disorder—Capecitabine—prostate cancer	6.83e-05	0.000342	CcSEcCtD
Valsartan—Fatigue—Capecitabine—prostate cancer	6.82e-05	0.000342	CcSEcCtD
Valsartan—Mental disorder—Epirubicin—prostate cancer	6.8e-05	0.00034	CcSEcCtD
Valsartan—Constipation—Capecitabine—prostate cancer	6.77e-05	0.000339	CcSEcCtD
Valsartan—Malnutrition—Epirubicin—prostate cancer	6.76e-05	0.000338	CcSEcCtD
Valsartan—Diarrhoea—Etoposide—prostate cancer	6.73e-05	0.000337	CcSEcCtD
Valsartan—Anorexia—Prednisone—prostate cancer	6.72e-05	0.000336	CcSEcCtD
Valsartan—Gastrointestinal pain—Docetaxel—prostate cancer	6.68e-05	0.000335	CcSEcCtD
Valsartan—Cardiac disorder—Doxorubicin—prostate cancer	6.66e-05	0.000334	CcSEcCtD
Valsartan—Flatulence—Epirubicin—prostate cancer	6.66e-05	0.000333	CcSEcCtD
Valsartan—Dysgeusia—Epirubicin—prostate cancer	6.62e-05	0.000331	CcSEcCtD
Valsartan—Back pain—Epirubicin—prostate cancer	6.53e-05	0.000327	CcSEcCtD
Valsartan—Angiopathy—Doxorubicin—prostate cancer	6.51e-05	0.000326	CcSEcCtD
Valsartan—Dizziness—Etoposide—prostate cancer	6.5e-05	0.000326	CcSEcCtD
Valsartan—Muscle spasms—Epirubicin—prostate cancer	6.49e-05	0.000325	CcSEcCtD
Valsartan—Immune system disorder—Doxorubicin—prostate cancer	6.49e-05	0.000325	CcSEcCtD
Valsartan—Gastrointestinal pain—Capecitabine—prostate cancer	6.47e-05	0.000324	CcSEcCtD
Valsartan—Mediastinal disorder—Doxorubicin—prostate cancer	6.47e-05	0.000324	CcSEcCtD
Valsartan—Abdominal pain—Docetaxel—prostate cancer	6.46e-05	0.000323	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Prednisone—prostate cancer	6.42e-05	0.000321	CcSEcCtD
Valsartan—Insomnia—Prednisone—prostate cancer	6.38e-05	0.000319	CcSEcCtD
Valsartan—Vision blurred—Epirubicin—prostate cancer	6.37e-05	0.000319	CcSEcCtD
Valsartan—Alopecia—Doxorubicin—prostate cancer	6.35e-05	0.000318	CcSEcCtD
Valsartan—Paraesthesia—Prednisone—prostate cancer	6.33e-05	0.000317	CcSEcCtD
Valsartan—Mental disorder—Doxorubicin—prostate cancer	6.29e-05	0.000315	CcSEcCtD
Valsartan—Urticaria—Capecitabine—prostate cancer	6.29e-05	0.000315	CcSEcCtD
Valsartan—Abdominal pain—Capecitabine—prostate cancer	6.26e-05	0.000313	CcSEcCtD
Valsartan—Vomiting—Etoposide—prostate cancer	6.25e-05	0.000313	CcSEcCtD
Valsartan—Malnutrition—Doxorubicin—prostate cancer	6.25e-05	0.000313	CcSEcCtD
Valsartan—Dyspepsia—Prednisone—prostate cancer	6.21e-05	0.000311	CcSEcCtD
Valsartan—Rash—Etoposide—prostate cancer	6.2e-05	0.00031	CcSEcCtD
Valsartan—Dermatitis—Etoposide—prostate cancer	6.2e-05	0.00031	CcSEcCtD
Valsartan—Headache—Etoposide—prostate cancer	6.16e-05	0.000308	CcSEcCtD
Valsartan—Flatulence—Doxorubicin—prostate cancer	6.16e-05	0.000308	CcSEcCtD
Valsartan—Decreased appetite—Prednisone—prostate cancer	6.13e-05	0.000307	CcSEcCtD
Valsartan—Dysgeusia—Doxorubicin—prostate cancer	6.12e-05	0.000306	CcSEcCtD
Valsartan—Fatigue—Prednisone—prostate cancer	6.08e-05	0.000304	CcSEcCtD
Valsartan—Vertigo—Epirubicin—prostate cancer	6.07e-05	0.000304	CcSEcCtD
Valsartan—Syncope—Epirubicin—prostate cancer	6.06e-05	0.000303	CcSEcCtD
Valsartan—Back pain—Doxorubicin—prostate cancer	6.05e-05	0.000303	CcSEcCtD
Valsartan—Constipation—Prednisone—prostate cancer	6.03e-05	0.000302	CcSEcCtD
Valsartan—Hypersensitivity—Docetaxel—prostate cancer	6.02e-05	0.000301	CcSEcCtD
Valsartan—Muscle spasms—Doxorubicin—prostate cancer	6.01e-05	0.000301	CcSEcCtD
Valsartan—Palpitations—Epirubicin—prostate cancer	5.97e-05	0.000299	CcSEcCtD
Valsartan—Loss of consciousness—Epirubicin—prostate cancer	5.94e-05	0.000297	CcSEcCtD
Valsartan—Cough—Epirubicin—prostate cancer	5.9e-05	0.000295	CcSEcCtD
Valsartan—Vision blurred—Doxorubicin—prostate cancer	5.89e-05	0.000295	CcSEcCtD
Valsartan—Asthenia—Docetaxel—prostate cancer	5.86e-05	0.000294	CcSEcCtD
Valsartan—Nausea—Etoposide—prostate cancer	5.84e-05	0.000292	CcSEcCtD
Valsartan—Hypersensitivity—Capecitabine—prostate cancer	5.83e-05	0.000292	CcSEcCtD
Valsartan—Pruritus—Docetaxel—prostate cancer	5.78e-05	0.000289	CcSEcCtD
Valsartan—Gastrointestinal pain—Prednisone—prostate cancer	5.76e-05	0.000289	CcSEcCtD
Valsartan—Arthralgia—Epirubicin—prostate cancer	5.75e-05	0.000288	CcSEcCtD
Valsartan—Chest pain—Epirubicin—prostate cancer	5.75e-05	0.000288	CcSEcCtD
Valsartan—Myalgia—Epirubicin—prostate cancer	5.75e-05	0.000288	CcSEcCtD
Valsartan—Anxiety—Epirubicin—prostate cancer	5.73e-05	0.000287	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	5.71e-05	0.000286	CcSEcCtD
Valsartan—Asthenia—Capecitabine—prostate cancer	5.68e-05	0.000284	CcSEcCtD
Valsartan—Dry mouth—Epirubicin—prostate cancer	5.62e-05	0.000282	CcSEcCtD
Valsartan—Vertigo—Doxorubicin—prostate cancer	5.62e-05	0.000281	CcSEcCtD
Valsartan—Syncope—Doxorubicin—prostate cancer	5.61e-05	0.000281	CcSEcCtD
Valsartan—Urticaria—Prednisone—prostate cancer	5.6e-05	0.00028	CcSEcCtD
Valsartan—Pruritus—Capecitabine—prostate cancer	5.6e-05	0.00028	CcSEcCtD
Valsartan—Diarrhoea—Docetaxel—prostate cancer	5.59e-05	0.00028	CcSEcCtD
Valsartan—Abdominal pain—Prednisone—prostate cancer	5.57e-05	0.000279	CcSEcCtD
Valsartan—Palpitations—Doxorubicin—prostate cancer	5.52e-05	0.000276	CcSEcCtD
Valsartan—Anaphylactic shock—Epirubicin—prostate cancer	5.51e-05	0.000276	CcSEcCtD
Valsartan—Oedema—Epirubicin—prostate cancer	5.51e-05	0.000276	CcSEcCtD
Valsartan—Loss of consciousness—Doxorubicin—prostate cancer	5.49e-05	0.000275	CcSEcCtD
Valsartan—Infection—Epirubicin—prostate cancer	5.48e-05	0.000274	CcSEcCtD
Valsartan—Cough—Doxorubicin—prostate cancer	5.45e-05	0.000273	CcSEcCtD
Valsartan—Shock—Epirubicin—prostate cancer	5.42e-05	0.000272	CcSEcCtD
Valsartan—Diarrhoea—Capecitabine—prostate cancer	5.41e-05	0.000271	CcSEcCtD
Valsartan—Nervous system disorder—Epirubicin—prostate cancer	5.41e-05	0.000271	CcSEcCtD
Valsartan—Dizziness—Docetaxel—prostate cancer	5.41e-05	0.000271	CcSEcCtD
Valsartan—Thrombocytopenia—Epirubicin—prostate cancer	5.4e-05	0.00027	CcSEcCtD
Valsartan—Skin disorder—Epirubicin—prostate cancer	5.36e-05	0.000268	CcSEcCtD
Valsartan—Chest pain—Doxorubicin—prostate cancer	5.32e-05	0.000266	CcSEcCtD
Valsartan—Arthralgia—Doxorubicin—prostate cancer	5.32e-05	0.000266	CcSEcCtD
Valsartan—Myalgia—Doxorubicin—prostate cancer	5.32e-05	0.000266	CcSEcCtD
Valsartan—Anxiety—Doxorubicin—prostate cancer	5.3e-05	0.000265	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.28e-05	0.000265	CcSEcCtD
Valsartan—Anorexia—Epirubicin—prostate cancer	5.26e-05	0.000263	CcSEcCtD
Valsartan—Dizziness—Capecitabine—prostate cancer	5.23e-05	0.000262	CcSEcCtD
Valsartan—Dry mouth—Doxorubicin—prostate cancer	5.2e-05	0.000261	CcSEcCtD
Valsartan—Vomiting—Docetaxel—prostate cancer	5.2e-05	0.00026	CcSEcCtD
Valsartan—Hypersensitivity—Prednisone—prostate cancer	5.19e-05	0.00026	CcSEcCtD
Valsartan—Rash—Docetaxel—prostate cancer	5.15e-05	0.000258	CcSEcCtD
Valsartan—Hypotension—Epirubicin—prostate cancer	5.15e-05	0.000258	CcSEcCtD
Valsartan—Dermatitis—Docetaxel—prostate cancer	5.15e-05	0.000258	CcSEcCtD
Valsartan—Headache—Docetaxel—prostate cancer	5.12e-05	0.000256	CcSEcCtD
Valsartan—Anaphylactic shock—Doxorubicin—prostate cancer	5.1e-05	0.000255	CcSEcCtD
Valsartan—Oedema—Doxorubicin—prostate cancer	5.1e-05	0.000255	CcSEcCtD
Valsartan—Infection—Doxorubicin—prostate cancer	5.07e-05	0.000254	CcSEcCtD
Valsartan—Asthenia—Prednisone—prostate cancer	5.06e-05	0.000253	CcSEcCtD
Valsartan—Vomiting—Capecitabine—prostate cancer	5.03e-05	0.000252	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.02e-05	0.000251	CcSEcCtD
Valsartan—Shock—Doxorubicin—prostate cancer	5.02e-05	0.000251	CcSEcCtD
Valsartan—Nervous system disorder—Doxorubicin—prostate cancer	5e-05	0.00025	CcSEcCtD
Valsartan—Thrombocytopenia—Doxorubicin—prostate cancer	4.99e-05	0.00025	CcSEcCtD
Valsartan—Rash—Capecitabine—prostate cancer	4.99e-05	0.00025	CcSEcCtD
Valsartan—Pruritus—Prednisone—prostate cancer	4.99e-05	0.00025	CcSEcCtD
Valsartan—Insomnia—Epirubicin—prostate cancer	4.99e-05	0.00025	CcSEcCtD
Valsartan—Dermatitis—Capecitabine—prostate cancer	4.99e-05	0.00025	CcSEcCtD
Valsartan—Headache—Capecitabine—prostate cancer	4.96e-05	0.000248	CcSEcCtD
Valsartan—Skin disorder—Doxorubicin—prostate cancer	4.96e-05	0.000248	CcSEcCtD
Valsartan—Paraesthesia—Epirubicin—prostate cancer	4.95e-05	0.000248	CcSEcCtD
Valsartan—Dyspnoea—Epirubicin—prostate cancer	4.92e-05	0.000246	CcSEcCtD
Valsartan—Somnolence—Epirubicin—prostate cancer	4.9e-05	0.000245	CcSEcCtD
Valsartan—Anorexia—Doxorubicin—prostate cancer	4.86e-05	0.000243	CcSEcCtD
Valsartan—Nausea—Docetaxel—prostate cancer	4.86e-05	0.000243	CcSEcCtD
Valsartan—Dyspepsia—Epirubicin—prostate cancer	4.85e-05	0.000243	CcSEcCtD
Valsartan—Diarrhoea—Prednisone—prostate cancer	4.82e-05	0.000241	CcSEcCtD
Valsartan—Decreased appetite—Epirubicin—prostate cancer	4.79e-05	0.00024	CcSEcCtD
Valsartan—Hypotension—Doxorubicin—prostate cancer	4.77e-05	0.000239	CcSEcCtD
Valsartan—Gastrointestinal disorder—Epirubicin—prostate cancer	4.76e-05	0.000238	CcSEcCtD
Valsartan—Fatigue—Epirubicin—prostate cancer	4.75e-05	0.000238	CcSEcCtD
Valsartan—Constipation—Epirubicin—prostate cancer	4.71e-05	0.000236	CcSEcCtD
Valsartan—Nausea—Capecitabine—prostate cancer	4.7e-05	0.000235	CcSEcCtD
Valsartan—Dizziness—Prednisone—prostate cancer	4.66e-05	0.000233	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.65e-05	0.000233	CcSEcCtD
Valsartan—Insomnia—Doxorubicin—prostate cancer	4.61e-05	0.000231	CcSEcCtD
Valsartan—Paraesthesia—Doxorubicin—prostate cancer	4.58e-05	0.000229	CcSEcCtD
Valsartan—Dyspnoea—Doxorubicin—prostate cancer	4.55e-05	0.000228	CcSEcCtD
Valsartan—Somnolence—Doxorubicin—prostate cancer	4.54e-05	0.000227	CcSEcCtD
Valsartan—Gastrointestinal pain—Epirubicin—prostate cancer	4.51e-05	0.000226	CcSEcCtD
Valsartan—Dyspepsia—Doxorubicin—prostate cancer	4.49e-05	0.000225	CcSEcCtD
Valsartan—Vomiting—Prednisone—prostate cancer	4.48e-05	0.000224	CcSEcCtD
Valsartan—Rash—Prednisone—prostate cancer	4.44e-05	0.000222	CcSEcCtD
Valsartan—Dermatitis—Prednisone—prostate cancer	4.44e-05	0.000222	CcSEcCtD
Valsartan—Decreased appetite—Doxorubicin—prostate cancer	4.43e-05	0.000222	CcSEcCtD
Valsartan—Headache—Prednisone—prostate cancer	4.42e-05	0.000221	CcSEcCtD
Valsartan—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.4e-05	0.00022	CcSEcCtD
Valsartan—Fatigue—Doxorubicin—prostate cancer	4.4e-05	0.00022	CcSEcCtD
Valsartan—Urticaria—Epirubicin—prostate cancer	4.38e-05	0.000219	CcSEcCtD
Valsartan—Constipation—Doxorubicin—prostate cancer	4.36e-05	0.000218	CcSEcCtD
Valsartan—Abdominal pain—Epirubicin—prostate cancer	4.36e-05	0.000218	CcSEcCtD
Valsartan—Nausea—Prednisone—prostate cancer	4.19e-05	0.00021	CcSEcCtD
Valsartan—Gastrointestinal pain—Doxorubicin—prostate cancer	4.17e-05	0.000209	CcSEcCtD
Valsartan—Hypersensitivity—Epirubicin—prostate cancer	4.06e-05	0.000203	CcSEcCtD
Valsartan—Urticaria—Doxorubicin—prostate cancer	4.05e-05	0.000203	CcSEcCtD
Valsartan—Abdominal pain—Doxorubicin—prostate cancer	4.03e-05	0.000202	CcSEcCtD
Valsartan—Asthenia—Epirubicin—prostate cancer	3.96e-05	0.000198	CcSEcCtD
Valsartan—Pruritus—Epirubicin—prostate cancer	3.9e-05	0.000195	CcSEcCtD
Valsartan—Diarrhoea—Epirubicin—prostate cancer	3.77e-05	0.000189	CcSEcCtD
Valsartan—Hypersensitivity—Doxorubicin—prostate cancer	3.76e-05	0.000188	CcSEcCtD
Valsartan—Asthenia—Doxorubicin—prostate cancer	3.66e-05	0.000183	CcSEcCtD
Valsartan—Dizziness—Epirubicin—prostate cancer	3.65e-05	0.000182	CcSEcCtD
Valsartan—Pruritus—Doxorubicin—prostate cancer	3.61e-05	0.000181	CcSEcCtD
Valsartan—Vomiting—Epirubicin—prostate cancer	3.51e-05	0.000175	CcSEcCtD
Valsartan—Diarrhoea—Doxorubicin—prostate cancer	3.49e-05	0.000175	CcSEcCtD
Valsartan—Rash—Epirubicin—prostate cancer	3.48e-05	0.000174	CcSEcCtD
Valsartan—Dermatitis—Epirubicin—prostate cancer	3.47e-05	0.000174	CcSEcCtD
Valsartan—Headache—Epirubicin—prostate cancer	3.45e-05	0.000173	CcSEcCtD
Valsartan—Dizziness—Doxorubicin—prostate cancer	3.37e-05	0.000169	CcSEcCtD
Valsartan—Nausea—Epirubicin—prostate cancer	3.27e-05	0.000164	CcSEcCtD
Valsartan—Vomiting—Doxorubicin—prostate cancer	3.24e-05	0.000162	CcSEcCtD
Valsartan—Rash—Doxorubicin—prostate cancer	3.22e-05	0.000161	CcSEcCtD
Valsartan—Dermatitis—Doxorubicin—prostate cancer	3.21e-05	0.000161	CcSEcCtD
Valsartan—Headache—Doxorubicin—prostate cancer	3.2e-05	0.00016	CcSEcCtD
Valsartan—Nausea—Doxorubicin—prostate cancer	3.03e-05	0.000152	CcSEcCtD
Valsartan—ALB—Metabolism—GSTO1—prostate cancer	1.19e-05	0.000129	CbGpPWpGaD
Valsartan—ALB—Metabolism—HSD3B2—prostate cancer	1.19e-05	0.000129	CbGpPWpGaD
Valsartan—ALB—Metabolism—NAT2—prostate cancer	1.19e-05	0.000129	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP3A5—prostate cancer	1.18e-05	0.000128	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KDR—prostate cancer	1.18e-05	0.000128	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CAV1—prostate cancer	1.18e-05	0.000128	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—RXRA—prostate cancer	1.17e-05	0.000126	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ESR1—prostate cancer	1.15e-05	0.000125	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—prostate cancer	1.14e-05	0.000124	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PDHA1—prostate cancer	1.14e-05	0.000124	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA3—prostate cancer	1.14e-05	0.000124	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TCN2—prostate cancer	1.14e-05	0.000124	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—UCP3—prostate cancer	1.14e-05	0.000124	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.14e-05	0.000124	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLCB2—prostate cancer	1.14e-05	0.000123	CbGpPWpGaD
Valsartan—ALB—Metabolism—LRP2—prostate cancer	1.14e-05	0.000123	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2C18—prostate cancer	1.14e-05	0.000123	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CG—prostate cancer	1.14e-05	0.000123	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.13e-05	0.000123	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BAD—prostate cancer	1.12e-05	0.000122	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—COMT—prostate cancer	1.12e-05	0.000122	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTP1—prostate cancer	1.12e-05	0.000121	CbGpPWpGaD
Valsartan—ALB—Metabolism—P4HB—prostate cancer	1.12e-05	0.000121	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ITPR1—prostate cancer	1.1e-05	0.000119	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC22A3—prostate cancer	1.09e-05	0.000118	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HSD3B1—prostate cancer	1.09e-05	0.000118	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APC—prostate cancer	1.09e-05	0.000118	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CG—prostate cancer	1.09e-05	0.000118	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC22A1—prostate cancer	1.09e-05	0.000118	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PPARA—prostate cancer	1.09e-05	0.000118	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.08e-05	0.000117	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGF—prostate cancer	1.08e-05	0.000116	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IRS1—prostate cancer	1.08e-05	0.000116	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CG—prostate cancer	1.07e-05	0.000116	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—INS—prostate cancer	1.07e-05	0.000116	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.07e-05	0.000116	CbGpPWpGaD
Valsartan—ALB—Hemostasis—EGF—prostate cancer	1.06e-05	0.000115	CbGpPWpGaD
Valsartan—ALB—Metabolism—SULT2A1—prostate cancer	1.06e-05	0.000115	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—prostate cancer	1.06e-05	0.000115	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CREBBP—prostate cancer	1.05e-05	0.000114	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TBXAS1—prostate cancer	1.05e-05	0.000113	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA4—prostate cancer	1.05e-05	0.000113	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GSK3B—prostate cancer	1.04e-05	0.000113	CbGpPWpGaD
Valsartan—ALB—Metabolism—MED12—prostate cancer	1.04e-05	0.000113	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TYMS—prostate cancer	1.04e-05	0.000113	CbGpPWpGaD
Valsartan—ALB—Metabolism—GNG5—prostate cancer	1.03e-05	0.000112	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—INS—prostate cancer	1.03e-05	0.000112	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTM1—prostate cancer	1.03e-05	0.000111	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.02e-05	0.000111	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA2—prostate cancer	1.02e-05	0.00011	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CREBBP—prostate cancer	1.01e-05	0.000109	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LPL—prostate cancer	1.01e-05	0.000109	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SULT1A1—prostate cancer	1.01e-05	0.000109	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCG5—prostate cancer	1.01e-05	0.000109	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CD—prostate cancer	9.98e-06	0.000108	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CREBBP—prostate cancer	9.97e-06	0.000108	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF1—prostate cancer	9.96e-06	0.000108	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOA3—prostate cancer	9.96e-06	0.000108	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EGFR—prostate cancer	9.91e-06	0.000107	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF1—prostate cancer	9.84e-06	0.000107	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA1—prostate cancer	9.84e-06	0.000107	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	9.79e-06	0.000106	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CA—prostate cancer	9.74e-06	0.000105	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP1A1—prostate cancer	9.74e-06	0.000105	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HSD3B2—prostate cancer	9.73e-06	0.000105	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTO1—prostate cancer	9.73e-06	0.000105	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NAT2—prostate cancer	9.73e-06	0.000105	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ERCC2—prostate cancer	9.66e-06	0.000105	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAP2K1—prostate cancer	9.63e-06	0.000104	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CD—prostate cancer	9.56e-06	0.000104	CbGpPWpGaD
Valsartan—ALB—Metabolism—HPGDS—prostate cancer	9.5e-06	0.000103	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CA—prostate cancer	9.47e-06	0.000103	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SERPINE1—prostate cancer	9.46e-06	0.000102	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CD—prostate cancer	9.45e-06	0.000102	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2C19—prostate cancer	9.44e-06	0.000102	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NOS3—prostate cancer	9.42e-06	0.000102	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—KRAS—prostate cancer	9.36e-06	0.000101	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	9.35e-06	0.000101	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINE1—prostate cancer	9.35e-06	0.000101	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLCB2—prostate cancer	9.32e-06	0.000101	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2C18—prostate cancer	9.32e-06	0.000101	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LRP2—prostate cancer	9.32e-06	0.000101	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTT1—prostate cancer	9.21e-06	9.98e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ACHE—prostate cancer	9.21e-06	9.98e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGF2—prostate cancer	9.16e-06	9.92e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—P4HB—prostate cancer	9.14e-06	9.9e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2A6—prostate cancer	9.11e-06	9.86e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTHFR—prostate cancer	9.08e-06	9.83e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	9.07e-06	9.82e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOS3—prostate cancer	9.03e-06	9.78e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS3—prostate cancer	8.92e-06	9.66e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARA—prostate cancer	8.91e-06	9.64e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC22A1—prostate cancer	8.9e-06	9.63e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKR1C3—prostate cancer	8.86e-06	9.59e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PRKACB—prostate cancer	8.81e-06	9.54e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	8.79e-06	9.52e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JAK2—prostate cancer	8.78e-06	9.5e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP17A1—prostate cancer	8.72e-06	9.44e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CB—prostate cancer	8.7e-06	9.42e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—JAK2—prostate cancer	8.67e-06	9.39e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SULT2A1—prostate cancer	8.67e-06	9.39e-05	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—CREBBP—prostate cancer	8.63e-06	9.34e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—prostate cancer	8.62e-06	9.33e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	8.6e-06	9.31e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CA—prostate cancer	8.6e-06	9.31e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MDM2—prostate cancer	8.57e-06	9.28e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MED12—prostate cancer	8.53e-06	9.24e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GNG5—prostate cancer	8.46e-06	9.16e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ERBB2—prostate cancer	8.45e-06	9.15e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CAV1—prostate cancer	8.37e-06	9.07e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CB—prostate cancer	8.34e-06	9.03e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOA2—prostate cancer	8.31e-06	9e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CB—prostate cancer	8.24e-06	8.92e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOA3—prostate cancer	8.15e-06	8.83e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—prostate cancer	8.01e-06	8.67e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	8.01e-06	8.67e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8e-06	8.66e-05	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—prostate cancer	7.96e-06	8.62e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC5A5—prostate cancer	7.93e-06	8.58e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1B—prostate cancer	7.82e-06	8.47e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HPGDS—prostate cancer	7.78e-06	8.42e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2E1—prostate cancer	7.74e-06	8.39e-05	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—prostate cancer	7.74e-06	8.38e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2C19—prostate cancer	7.73e-06	8.37e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CASP3—prostate cancer	7.67e-06	8.3e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NQO1—prostate cancer	7.66e-06	8.29e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL2—prostate cancer	7.66e-06	8.29e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CG—prostate cancer	7.63e-06	8.26e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—prostate cancer	7.62e-06	8.25e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IL2—prostate cancer	7.56e-06	8.19e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—TH—prostate cancer	7.55e-06	8.17e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTT1—prostate cancer	7.54e-06	8.17e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ACHE—prostate cancer	7.54e-06	8.17e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTEN—prostate cancer	7.52e-06	8.14e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	7.5e-06	8.12e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP3A4—prostate cancer	7.47e-06	8.09e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCND1—prostate cancer	7.46e-06	8.08e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2A6—prostate cancer	7.45e-06	8.07e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	7.43e-06	8.04e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	7.43e-06	8.04e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CTNNB1—prostate cancer	7.39e-06	8e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1B1—prostate cancer	7.34e-06	7.95e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKR1C3—prostate cancer	7.25e-06	7.85e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—prostate cancer	7.25e-06	7.85e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—INS—prostate cancer	7.22e-06	7.82e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1A—prostate cancer	7.22e-06	7.82e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PRKACB—prostate cancer	7.21e-06	7.81e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTEN—prostate cancer	7.2e-06	7.8e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—EP300—prostate cancer	7.17e-06	7.76e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP17A1—prostate cancer	7.14e-06	7.73e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GGT1—prostate cancer	7.11e-06	7.7e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CREBBP—prostate cancer	7.07e-06	7.66e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	7.04e-06	7.62e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—prostate cancer	7.03e-06	7.61e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NCOA1—prostate cancer	7e-06	7.58e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP19A1—prostate cancer	6.9e-06	7.47e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EP300—prostate cancer	6.87e-06	7.44e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOA2—prostate cancer	6.8e-06	7.37e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—EP300—prostate cancer	6.79e-06	7.35e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CD—prostate cancer	6.7e-06	7.26e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SRC—prostate cancer	6.68e-06	7.23e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—RXRA—prostate cancer	6.66e-06	7.21e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SRC—prostate cancer	6.6e-06	7.15e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—prostate cancer	6.51e-06	7.04e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC5A5—prostate cancer	6.49e-06	7.03e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	6.48e-06	7.02e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—STAT3—prostate cancer	6.44e-06	6.98e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—prostate cancer	6.43e-06	6.96e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—COMT—prostate cancer	6.42e-06	6.95e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTP1—prostate cancer	6.39e-06	6.92e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2E1—prostate cancer	6.34e-06	6.86e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NOS3—prostate cancer	6.33e-06	6.86e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ITPR1—prostate cancer	6.28e-06	6.8e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NQO1—prostate cancer	6.27e-06	6.79e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	6.18e-06	6.69e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TH—prostate cancer	6.18e-06	6.69e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	6.14e-06	6.65e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP3A4—prostate cancer	6.11e-06	6.62e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	6.08e-06	6.58e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1B1—prostate cancer	6.01e-06	6.51e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MYC—prostate cancer	5.99e-06	6.48e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—prostate cancer	5.97e-06	6.47e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—TYMS—prostate cancer	5.94e-06	6.43e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—prostate cancer	5.9e-06	6.39e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTM1—prostate cancer	5.87e-06	6.35e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EGFR—prostate cancer	5.85e-06	6.34e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CB—prostate cancer	5.84e-06	6.33e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GGT1—prostate cancer	5.82e-06	6.3e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—prostate cancer	5.79e-06	6.27e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—LPL—prostate cancer	5.76e-06	6.24e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NCOA1—prostate cancer	5.73e-06	6.21e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP19A1—prostate cancer	5.65e-06	6.12e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1A1—prostate cancer	5.56e-06	6.02e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KRAS—prostate cancer	5.53e-06	5.99e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ERCC2—prostate cancer	5.52e-06	5.97e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—KRAS—prostate cancer	5.46e-06	5.92e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—RXRA—prostate cancer	5.45e-06	5.9e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.3e-06	5.74e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CA—prostate cancer	5.3e-06	5.74e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—COMT—prostate cancer	5.25e-06	5.69e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTP1—prostate cancer	5.23e-06	5.66e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTHFR—prostate cancer	5.19e-06	5.62e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ITPR1—prostate cancer	5.14e-06	5.57e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARA—prostate cancer	5.09e-06	5.51e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CA—prostate cancer	5.08e-06	5.5e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.06e-06	5.48e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTEN—prostate cancer	5.05e-06	5.47e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CA—prostate cancer	5.02e-06	5.44e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—prostate cancer	4.92e-06	5.32e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TYMS—prostate cancer	4.86e-06	5.26e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—prostate cancer	4.86e-06	5.26e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—EP300—prostate cancer	4.82e-06	5.22e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTM1—prostate cancer	4.8e-06	5.2e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CAV1—prostate cancer	4.78e-06	5.18e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPL—prostate cancer	4.72e-06	5.11e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.57e-06	4.95e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1A1—prostate cancer	4.55e-06	4.93e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ERCC2—prostate cancer	4.52e-06	4.89e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—prostate cancer	4.5e-06	4.87e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CG—prostate cancer	4.36e-06	4.72e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—prostate cancer	4.33e-06	4.69e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTHFR—prostate cancer	4.25e-06	4.6e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARA—prostate cancer	4.17e-06	4.51e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—prostate cancer	4.15e-06	4.49e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—INS—prostate cancer	4.13e-06	4.47e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—prostate cancer	4.1e-06	4.44e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CREBBP—prostate cancer	4.04e-06	4.37e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CAV1—prostate cancer	3.92e-06	4.24e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CD—prostate cancer	3.83e-06	4.15e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.74e-06	4.05e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NOS3—prostate cancer	3.62e-06	3.92e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CG—prostate cancer	3.57e-06	3.86e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CA—prostate cancer	3.56e-06	3.86e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—INS—prostate cancer	3.38e-06	3.66e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CB—prostate cancer	3.34e-06	3.62e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—prostate cancer	3.31e-06	3.58e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CREBBP—prostate cancer	3.31e-06	3.58e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CD—prostate cancer	3.14e-06	3.4e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NOS3—prostate cancer	2.96e-06	3.21e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—prostate cancer	2.91e-06	3.15e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTEN—prostate cancer	2.89e-06	3.12e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—EP300—prostate cancer	2.75e-06	2.98e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CB—prostate cancer	2.73e-06	2.96e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—prostate cancer	2.71e-06	2.93e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTEN—prostate cancer	2.36e-06	2.56e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—EP300—prostate cancer	2.25e-06	2.44e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CA—prostate cancer	2.04e-06	2.2e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.67e-06	1.8e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—prostate cancer	1.66e-06	1.8e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—prostate cancer	1.36e-06	1.47e-05	CbGpPWpGaD
